Research · Sep 3, 2026
[ZTS] Zoetis Thesis 2026: Companion Animal Pricing Power Anchors Premium Margin Leadership
Zoetis Inc. FY2025 revenue ~$9-9.3B (+5-7%) with adj. EPS ~$6.20-6.50 reflecting continued companion animal premium pricing power + selected new product launches (Librela osteoarthritis + Solensia + selected) + Apoquel/Cytopoint dermatology continued growth + selected livestock cycle stability + selected international expansion. Largest global animal health company by revenue; spun off from Pfizer June 2013 (Pfizer Animal Health became Zoetis IPO February 2013 + completed full spin-off June 2013). 2 species segments: Companion Animal ~64% (Apoquel + Cytopoint allergic dermatitis franchise + Simparica/Simparica Trio parasiticide + Librela osteoarthritis monoclonal antibody launched 2023 + Solensia for cats launched 2022 + selected diagnostics + vaccines) + Livestock ~33% (cattle vaccines + swine + poultry + fish + selected). ~70% portfolio is patent-protected branded products. CEO Kristin Peck since January 1, 2020 (succeeded Juan Ramon Alaix CEO 2010-2020; Peck ex-Zoetis EVP + Group President; ~15-year career at Zoetis + Pfizer Animal Health pre-spin). Peck tenure executed continued companion animal premium pricing + selected new product launches (Librela 2023 — first-of-kind injectable osteoarthritis treatment for dogs; Solensia 2022) + selected operational excellence + selected international expansion + capital return acceleration. Librela US launch May 2023 (after EU 2020); FY2024 revenue ~$300-400M; FY2025 expected $500-700M; selected unique franchise. Capital return: dividend $1.74-1.80/share + buybacks $0.5-1.5B; net debt $5-6B; Baa1/BBB+ investment grade. FY2026 thesis: companion animal pricing + new product launches + capital return. Risks: pet ownership cycle, generic substitution (Apoquel patent expiry late 2020s), livestock cyclical.